Analysis of Price Transparency via National Cancer Institute–Designated Cancer Centers’ Chargemasters for Prostate Cancer Radiation Therapy
Open Access
- 1 March 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (3) , 409-412
Abstract
One in 3 Americans experience financial distress as a result of medical care, and patients with cancer are twice as likely to file for bankruptcy as patients without cancer.1-3 Price transparency has been proposed as one of the potential solutions to high-cost care by empowering patients to budget for expected costs, apply for financial assistance earlier in their treatment course when required, engage in shared decision-making with their physicians around costs, and comparison shop across facilities.4Keywords
This publication has 10 references indexed in Scilit:
- The Commercial Differential for Hospital PricesJAMA, 2019
- Skepticism about new US Government hospital pricing transparency ruleThe Lancet Oncology, 2019
- The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United StatesJournal of Oncology, 2019
- Mystery Of The Chargemaster: Examining The Role Of Hospital List Prices In What Patients Actually PayHealth Affairs, 2017
- US Hospitals Are Still Using Chargemaster Markups To Maximize RevenuesHealth Affairs, 2016
- Improving Price Transparency in Cancer CareJournal of Oncology Practice, 2016
- Financial Toxicity of Cancer Care: It’s Time to InterveneJNCI: Journal of the National Cancer Institute, 2015
- A Census of State Health Care Price Transparency WebsitesJAMA, 2013
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer DiagnosisHealth Affairs, 2013
- National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008Journal of Clinical Oncology, 2011